NephroGenex to Present at the Cowen and Company 35th Annual Health Care Conference
NephroGenex, Inc. (Nasdaq:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, today announced that Chief Executive Officer Pierre Legault and President and Chief Scientific Officer J. Wesley Fox will present a corporate overview of the Company and meet with investors at the Cowen and Company 35th Annual Health Care Conference in Boston.
The presentation will take place on Wednesday, March 4 at 8:00 am EST at the Boston Marriott Copley Place Hotel.
Live and archived webcasts of the presentation will be accessible from the Company’s website at http://nephrogenex.investorhq.businesswire.com/events-calendar. A replay will be available for 30 days following the event.
In the presentation, Mr. Legault and Mr. Fox will review the Company’s Pyridorin clinical program for the treatment of diabetic nephropathy, a chronic, degenerative disease of the kidney affecting approximately 6 million patients in the U.S. for whom there are few therapeutic options. The Company launched its Phase 3 trial with Pyridorin in the second quarter of 2014.
About NephroGenex, Inc.
NephroGenex (Nasdaq: NRX) is a clinical-stage pharmaceutical company focused on developing therapeutics to treat kidney diseases caused by pathogenic oxidative chemistries. Since our inception, we have collaborated with the leading scientific experts in pathogenic oxidative chemistries to build a strong portfolio of intellectual property and novel acting drug candidates. Our clinical program has been done in collaboration with world leading clinical investigators in kidney disease. Our product pipeline includes an oral formulation of Pyridorin, which is being developed as a chronic, therapeutic agent to slow the progression of diabetic nephropathy, as well as an intravenous formulation of Pyridorin to treat specific types of acute kidney injury.
Cautionary Note on Forward-Looking Statements
This press release contains certain statements that are, or may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “expects,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “will,” or words of similar meaning and include, but are not limited to, statements regarding the outlook for our future business and financial performance. Forward-looking statements are based on our current expectations and assumptions, which are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Actual outcomes and results may differ materially from those in the forward-looking statements due to global political, economic, business, competitive, market, regulatory and other factors and risks, including the items identified under “Part I-Item 1A-Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2013, filed with the Securities and Exchange Commission (“SEC”) on March 31, 2014, as well as in other filings that we may make with the SEC in the future. The forward-looking statements contained in this press release reflect our current views with respect to future events, and we do not undertake and specifically disclaim any obligation to update any forward-looking statements.
Sorry. No data so far.